Information on patient characteristics, acute GVHD, and skin biopsy
| Characteristic . | Value . |
|---|---|
| Patient characteristics | |
| Total no. of patients | 104 |
| Median age at allo-SCT, y (range) | 40.5 (19-61) |
| Male/female | 65/39 |
| Disease risk, low/high | 51/53 |
| HLA, match/mismatch | 72/32 |
| Donor, unrelated/related | 67/37 |
| Graft, BM/PB/CB | 89/11/4 |
| Conditioning, conventional/RIST | 78/26 |
| Median observation period, mo (range) | 13.7 (0.7-120.7) |
| Acute GVHD | |
| Stage skin (at the time of biopsy), 1/2/3/4 | 22/57/25/0 |
| Skin (the maximal severity), 1/2/3/4 | 16/25/52/11 |
| Gut, 0/1/2/3/4 | 69/9/8/15/3 |
| Liver, 0/1/2/3/4 | 82/5/3/9/5 |
| Grade (at the time of the biopsy), I/II/III/IV | 58/41/4/1 |
| Grade (the maximal severity), I/II/III/IV | 28/44/19/13 |
| Primary steroid treatment, yes/no | 46/58 |
| Second treatment, yes/no | 18/30 |
| Outcome of GVHD, improved/refractory | 84/20 |
| Skin lesion | |
| Median date of appearance, days (range) | 24 (5-81) |
| Median date of skin biopsy, days (range) | 31.5 (6-82) |
| Median date of highest stage of skin GVHD, days (range) | 34 (9-90) |
| No. of infiltrating CD8+ cells | 65 (2-305) |
| No. of infiltrating CD163+ cells | 132.5 (38-372) |
| No. of infiltrating CD1a+ cells | 7 (0-122) |
| Characteristic . | Value . |
|---|---|
| Patient characteristics | |
| Total no. of patients | 104 |
| Median age at allo-SCT, y (range) | 40.5 (19-61) |
| Male/female | 65/39 |
| Disease risk, low/high | 51/53 |
| HLA, match/mismatch | 72/32 |
| Donor, unrelated/related | 67/37 |
| Graft, BM/PB/CB | 89/11/4 |
| Conditioning, conventional/RIST | 78/26 |
| Median observation period, mo (range) | 13.7 (0.7-120.7) |
| Acute GVHD | |
| Stage skin (at the time of biopsy), 1/2/3/4 | 22/57/25/0 |
| Skin (the maximal severity), 1/2/3/4 | 16/25/52/11 |
| Gut, 0/1/2/3/4 | 69/9/8/15/3 |
| Liver, 0/1/2/3/4 | 82/5/3/9/5 |
| Grade (at the time of the biopsy), I/II/III/IV | 58/41/4/1 |
| Grade (the maximal severity), I/II/III/IV | 28/44/19/13 |
| Primary steroid treatment, yes/no | 46/58 |
| Second treatment, yes/no | 18/30 |
| Outcome of GVHD, improved/refractory | 84/20 |
| Skin lesion | |
| Median date of appearance, days (range) | 24 (5-81) |
| Median date of skin biopsy, days (range) | 31.5 (6-82) |
| Median date of highest stage of skin GVHD, days (range) | 34 (9-90) |
| No. of infiltrating CD8+ cells | 65 (2-305) |
| No. of infiltrating CD163+ cells | 132.5 (38-372) |
| No. of infiltrating CD1a+ cells | 7 (0-122) |
Disease risk low indicates acute leukemia in first remission; CML, in first chronic phase; MDS, refractory anemia or nonmalignant hematologic disease; disease risk high, all other diagnoses; HLA match, identical HLA-A, -B, and -DRB1 loci; HLA mismatch, at least one disparity at one of these loci; BM, bone marrow; PB, peripheral blood; CB, cord blood; and RIST, reduced intensity conditioning regimens.